Publications by authors named "Cecilia Monaldi"

Claim this Profile
S
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid Leukemia.
Manuela Mancini, Sara De Santis, Cecilia Monaldi, Fausto Castagnetti, Miriam Iezza

Clin Transl Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets.
Samantha Bruno, Enrica Borsi, Agnese Patuelli, Lorenza Bandini, Manuela Mancini, Cecilia Monaldi

Int J Mol Sci· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
Adela Benesova, Sara De Santis, Vaclava Polivkova, Pavla Pecherkova, Jitka Krizkova, Cecilia Monaldi

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.
Miriam Iezza, Sofia Cortesi, Emanuela Ottaviani, Manuela Mancini, Claudia Venturi, Cecilia Monaldi

Cells· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.
Manuela Mancini, Cecilia Monaldi, Sara De Santis, Cristina Papayannidis, Michela Rondoni

Biomark Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
Simona Soverini, Sara De Santis, Margherita Martelli, Cecilia Monaldi, Fausto Castagnetti

Leukemia· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors.
Manuela Mancini, Sara De Santis, Cecilia Monaldi, Fausto Castagnetti, Annalisa Lonetti

Front Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.
Sara De Santis, Cecilia Monaldi, Manuela Mancini, Samantha Bruno, Michele Cavo

Onco Targets Ther· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.
Manuela Mancini, Cecilia Monaldi, Sara De Santis, Michela Rondoni, Cristina Papayannidis

Cancers (Basel)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.
Samantha Bruno, Lorenza Bandini, Agnese Patuelli, Valentina Robustelli, Claudia Venturi, Cecilia Monaldi

Front Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.
Cecilia Monaldi, Sara De Santis, Manuela Mancini, Samantha Bruno, Michele Cavo

Mediterr J Hematol Infect Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities.
Samantha Bruno, Manuela Mancini, Sara De Santis, Cecilia Monaldi, Michele Cavo

Int J Mol Sci· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
Simona Soverini, Sara De Santis, Cecilia Monaldi, Samantha Bruno, Manuela Mancini

Int J Mol Sci· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.
Margherita Martelli, Cecilia Monaldi, Sara De Santis, Samantha Bruno, Manuela Mancini

Int J Mol Sci· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis.
Manuela Mancini, Sara De Santis, Cecilia Monaldi, Luana Bavaro, Margherita Martelli

Hematol Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.
Manuela Mancini, Fausto Castagnetti, Simona Soverini, Elisa Leo, Caterina De Benedittis, Cecilia Monaldi

J Cell Biochem· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis